microSelectron Digital (HDR-V3) Brachytherapy Afterloader for Cancer Treatment Receives Shonin Approval from Japanese Ministry of Health

Japanese Ministry of Health, Labor and Welfare (MHLW) granted Shonin approval to market the microSelectron® Digital (HDR-V3) afterloader in Japan.

Tokyo Japan — Wednesday, February 15, 2012

Nucletron, an Elekta company, the world's leading manufacturer of brachytherapy solutions, announced today that the Japanese Ministry of Health, Labor and Welfare (MHLW) granted Shonin approval to market the microSelectron® Digital (HDR-V3) afterloader in Japan.

Designed for precise and targeted treatment of cancer, the microSelectron Digital (HDR-V3) offers proven reliability in afterloading and has the world’s largest installed base. The scalable and upgradable platform, with 6, 18 or 30 channels, meets the needs of many brachytherapy patients and healthcare professionals.

Nucletron brachytherapy solutions treat cancer from the “inside out,” with the radiation source positioned directly inside or next to the tumor. This precise and accurate form of radiation has proven to be a highly effective treatment option, while also reducing the risk of unintended damage to healthy tissues and organs – reducing potential side effects for patients. This makes brachytherapy a complementary and valuable adjunct to any radiotherapy program.

Nucletron’s key technological advances have resulted in an integrated portfolio of treatment planning and delivery systems. With 35 years of experience, Nucletron continues to drive efficiency, efficacy, quality and safety in brachytherapy solutions.

Elekta acquired Nucletron in September 2011.

 

 

###

About Elekta

Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives.

Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,300 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb. Website: www.elekta.com.